68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: First human experience

Journal of Nuclear Medicine

Volumn 58, Issue 1, 2017, Pages 81-84

  Hope, Thomas A ^a,c   Truillet, Charles ^b   Ehman, Eric C ^d   Afshar Oromieh, Ali ^e   Aggarwal, Rahul ^a,c   Ryan, Charles J ^a,c   Carroll, Peter R ^c,f   Small, Eric J ^a,c   Evans, Michael J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Oncology: GU; PET; Prostate cancer; PSMA PET

Indexed keywords

APALUTAMIDE; BICALUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GALLIUM GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ANDROGEN RECEPTOR ANTAGONIST; ORGANOMETALLIC COMPOUND;

ADULT; ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CASE REPORT; CASTRATION SENSITIVE PROSTATE CANCER; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VIVO STUDY; INTRAGLUTEAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MOUSE; NONHUMAN; ORCHIECTOMY; PET SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; DIAGNOSTIC IMAGING; DRUG MONITORING; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; DRUG MONITORING; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85009085820     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.181800     Document Type: Article

References (25)

1. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807-1811.
2. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
3. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31:144-154.
4. Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934-1940.
5. Ceci F, Uprimny C, Nilica B, et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284-1294.
6. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18Ffluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185-1190.
7. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
8. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
9. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
10. Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: An emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012;2:985-994.
11. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108:9578-9582.
12. Wright GL, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
13. Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66.
14. Miyamoto DT, Lee RJ, Stott SL, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012;2:995-1003.
15. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.
16. Wollenweber SD, Ambwani S. Comparison of 4-class and continuous fat/water methods for whole-body, MR-based PET attenuation correction. IEEE Trans Nucl Sci. 2013;60:3391-3398.
17. Vallabhajosula S, Jhanwar Y, Tagawa S, et al. 99mTc-MIP-1404 planar and SPECT scan: imaging biomarker of androgen receptor (AR) signaling and prostate specific membrane antigen (PSMA) expression [abstract]. J Nucl Med. 2016;57(suppl 2):1541.
18. Schlenkhoff CD, Gaertner F, Essler M, Hauser S, Ahmadzadehfar H. 68Galabeled anti-prostate-specific membrane antigen peptide as marker for androgen deprivation therapy response in prostate cancer. Clin Nucl Med. 2016;41:423-425.
19. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-Therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-Analysis. Ann Intern Med. 2000;132:566-577.
20. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004;61:332-353.
21. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244.
22. Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006-1013.
23. Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
24. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-Targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170-1176.
25. DiPippo VA, Nguyen HM, Brown LG, Olson WC, Vessella RL, Corey E. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. Prostate. 2016;76:325-334.